➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
AstraZeneca
Moodys
Dow
Express Scripts

Last Updated: May 13, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Palovarotene

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Palovarotene?

Palovarotene is an investigational drug.

There have been 9 clinical trials for Palovarotene. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2017.

The most common disease conditions in clinical trials are Myositis Ossificans, Ossification, Heterotopic, and Dry Eye Syndromes. The leading clinical trial sponsors are Clementia Pharmaceuticals Inc., Ipsen, and [disabled in preview].

There are twenty-two US patents protecting this investigational drug and two hundred and four international patents.

Recent Clinical Trials for Palovarotene
TitleSponsorPhase
Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult SubjectsClementia Pharmaceuticals Inc.Phase 1
Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Palovarotene Ophthalmic Solution in Healthy Adult SubjectsIpsenPhase 1
Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Palovarotene Ophthalmic Solution in Healthy Adult SubjectsClementia Pharmaceuticals Inc.Phase 1

See all Palovarotene clinical trials

Clinical Trial Summary for Palovarotene

Top disease conditions for Palovarotene
Top clinical trial sponsors for Palovarotene

See all Palovarotene clinical trials

US Patents for Palovarotene

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Palovarotene   Get Started for $10 Therapeutic agent for keratoconjunctive disorders YAMAGUCHI UNIVERSITY (Yamaguchi, JP)   Get Started for $10
Palovarotene   Get Started for $10 Controlled release dosage form TRIASTEK, INC. (Nanjing, CN)   Get Started for $10
Palovarotene   Get Started for $10 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (Cambridge, MA)   Get Started for $10
Palovarotene   Get Started for $10 Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN)   Get Started for $10
Palovarotene   Get Started for $10 Composition and method for muscle repair and regeneration Thomas Jefferson University (Philadelphia, PA)   Get Started for $10
Palovarotene   Get Started for $10 Compartmented pharmaceutical dosage forms Triastek, Inc. (Nanjing, CN)   Get Started for $10
Palovarotene   Get Started for $10 Anti-ALK2 antibody Saitama Medical University (Saitama, JP) Daiichi Sankyo Company, limited (Tokyo, JP)   Get Started for $10
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Palovarotene

Drugname Country Document Number Estimated Expiration Related US Patent
Palovarotene Australia AU2013342882 2032-11-08   Get Started for $10
Palovarotene Australia AU2018217197 2032-11-08   Get Started for $10
Palovarotene Brazil BR112015010428 2032-11-08   Get Started for $10
Palovarotene Canada CA2890424 2032-11-08   Get Started for $10
Palovarotene Chile CL2015001225 2032-11-08   Get Started for $10
Palovarotene Chile CL2018001915 2032-11-08   Get Started for $10
Palovarotene China CN105188753 2032-11-08   Get Started for $10
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Boehringer Ingelheim
Merck
Harvard Business School
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.